Clinical trials: Arm
Primary Generalized (Osteo)Arthritis, Post-traumatic Arthrosis of Other Joints, Upper Arm
Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty
The purpose of this study is to demonstrate safety and efficacy of the Simpliciti Shoulder System in total shoulder arthroplasty.
- Trial name
- NCT01390038
- Testing
- Simpliciti™ Shoulder System
- Where
- 14 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Stryker Trauma and Extremities
Spinal Cord Injury
Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury
To determine whether functional electrical stimulation (FES) promotes neurological and physical recovery in patients with spinal cord injury (SCI).
- Trial name
- NCT01005615
- Testing
- Non-FES Upper Extremity Exercise, RT300-SLSA, from Restorative Therapies, Inc.
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.
Atopic Dermatitis
A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis
The purpose of this study is to investigate the effectiveness and safety of 2 concentrations of OPA-15406 compared to vehicle in participants with atopic dermatitis (AD).
- Trial name
- NCT02068352
- Testing
- OPA-15406, Vehicle ointment
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 121 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
- Trial name
- SERENITY (NCT02891226)
- Testing
- Mirikizumab
- Where
- 108 sites in United States, Australia and 12 more
- Volunteers
- 191 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Distal Radius Fractures
Fixation of Unstable Distal Radius Fractures
Wrist fractures are the most common type of fractures that occur in the shoulder, arm, and hand. Approximately 250,000 to 300,000 wrist fractures occur in the United States each year.
- Trial name
- NCT00654615
- Testing
- Intramedullary Radius Fixation (Micronail), Volar Plate Fixation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Wake Forest University
Lymphoma
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL. The main aims of the study are to evaluate: Side effect from the A+CHP Check how much A+CHP stays in their…
- Trial name
- NCT05673785
- Testing
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin
- Where
- 16 sites in China
- Volunteers
- 52 people
- Sponsor
- Takeda
Stroke
Upper Arm Training With Armeo Spring for Stroke
The purpose of this study is to assess the clinical outcomes of upper extremity training using the Armeo Spring system in a chronic post-stroke population with impaired upper extremity function.
- Trial name
- NCT01485354
- Testing
- Armeo Spring training
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Spaulding Rehabilitation Hospital
HIV
The Effect of Antacids and Multivitamins on Raltegravir
This study seeks to address the question of whether antacids or multivitamins influence the pharmacokinetics of raltegravir when co-administered.
- Trial name
- NCT01784302
- Testing
- Multivitamins, Sodium bicarbonate, Maalox Plus extra
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Helen Reynolds
Peripheral Arterial Disease, Critical Limb Ischemia
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)
This is a prospective, multicenter, single arm study designed to evaluate the safety and efficacy of the Temporary Bare Spur Stent System (Spur Stent System).
- Trial name
- DEEPER REVEAL (NCT05358353)
- Testing
- Bare Temporary Spur Stent System
- Where
- 48 sites in United States
- Volunteers
- 130 people
- Sponsor
- ReFlow Medical, Inc.
Metastatic Breast Cancer
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy.
- Trial name
- NCT00337103
- Testing
- Eribulin Mesylate, Capecitabine
- Where
- 169 sites in United States, Argentina and 21 more
- Volunteers
- 1,276 people
- Sponsor
- Eisai Inc.
Non-Germline BRCA Mutated Ovarian Cancer
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or…
- Trial name
- OPINION (NCT03402841)
- Testing
- Olaparib
- Where
- 91 sites in Austria, Belgium and 17 more
- Volunteers
- 279 people
- Sponsor
- AstraZeneca
Heart Failure
Intra-procedural Transthoracic EChocardiogram to Facilitate Left Bundle Branch Area Pacing (LBBAP)
The goal of this observational study is to learn more about whether or not the use of heart ultrasound during pacemaker implantation is helpful. The main questions this aims to answer are: 1.
- Trial name
- EC-LBBAP (NCT05646251)
- Testing
- Heart Ultrasound
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Geisinger Clinic
Hysterectomy, Postoperative
A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy
The main objective of this study is to demonstrate the efficacy and safety of multiple-dose application of three different oral doses of CG5503 IR (tapentadol immediate release) compared to placebo in women undergoing abdominal…
- Trial name
- NCT00478023
- Testing
- Morphine, CG5503 IR
- Where
- 52 sites in Hungary, Latvia and 7 more
- Volunteers
- 854 people
- Sponsor
- Grünenthal GmbH
Healthy Male Subjects
Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers
This is a randomized, double-blind, three-arm, parallel-group, single-dose study to demonstrate bioequivalence of ENZ215 and EU- and US-sourced Prolia after a single 60-mg dose administered subcutaneously in healthy adult male…
- Trial name
- NCT05245669
- Testing
- ENZ215, EU Sourced Prolia, US Sourced Prolia
- Where
- 2 sites in Bulgaria, Poland
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Enzene Biosciences Ltd.
Refractory Bone or Joint Infections
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.
- Trial name
- NCT02569541
- Testing
- sodium fusidate
- Where
- 19 sites in United States
- Volunteers
- 30 people
- Sponsor
- Arrevus Inc.
Alzheimer´s Disease
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to…
- Trial name
- NCT00818662
- Testing
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Where
- 41 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Baxalta now part of Shire
Prostate Cancer
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
In April 2011, the United States Food and Drug Administration (FDA) approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate…
- Trial name
- NCT01751451
- Testing
- Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
- Where
- 16 sites in United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-cell Acute Lymphoblastic Leukemia
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- Trial name
- BLAST (NCT01207388)
- Testing
- Blinatumomab
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 116 people
- Sponsor
- Amgen Research (Munich) GmbH